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Aging is a critical risk factor for Parkinson’s disease. Silibinin, a major flavonoid in
Silybum marianum, has been suggested to display neuroprotective properties against
various neurodegenerative diseases. In the present study, we observed that neonatal iron
(120μg/g body weight) supplementation resulted in significant abnormality of behavior
and depletion of striatal dopamine (DA) in the aging male and female rats while it did
not do so in the young male and female rats. No significant change in striatal serotonin
content was observed in the aging male and female rats with neonatal supplementation
of the same dose of iron. Furthermore, we found that the neonatal iron supplementation
resulted in significant increase in malondialdehyde (MDA) and decrease in glutathione
(GSH) in the substantia nigra (SN) of the aging male and female rats. No significant change
in content of MDA and GSH was observed in the cerebellum of the aging male and female
rats with the neonatal iron supplementation. Interestingly, silibinin (25 and 50mg/kg
body weight) treatment significantly and dose-dependently attenuated depletion of striatal
DA and improved abnormality of behavior in the aging male and female rats with the
neonatal iron supplementation. Moreover, silibinin significantly reduced MDA content and
increased GSH content in the SN of the aging male and female rats. Taken together, our
results indicate that elevated neonatal iron supplementation may result in neurochemical
and behavioral deficits in the male and female rats with aging and silibinin may exert
dopaminergic neuroprotection by maintaining redox balance.
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INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by cardinal fea-
tures, including resting tremor, rigidity, slowness of movement, and postural instability. It is due
to decreased dopamine (DA) content in the striatum as a result of progressive and selective
degeneration of dopaminergic neurons in the substantia nigra (SN). In recent years, more and more
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studies have demonstrated that the causes of PD are multi-
factorial, including aging, exposure to environmental toxins,
immune/inflammatory factors, genetic predisposition, and innate
characteristics of the nigrostriatal dopaminergic system in the
brain (Olanow and Tatton, 1999; Kidd, 2000; Gao et al., 2003;
Wang et al., 2005a,b, 2007a,b, 2011; Zhang et al., 2011; Con-
nolly and Lang, 2014). For a long time, because it is difficult
to obtain aging animals, young animals are often applied to PD
research. However, PD is a neurodegenerative disease that is
closely associated with aging. Among those factors that have the
potential to play a role in idiopathic PD, aging is a critical risk
factor for this disease (Yankner et al., 2008; Gureviciene et al.,
2009; Hindle, 2010). Epidemiological survey also exhibits that PD
affects about 1–2% of the population over the age of 65, and
incidence and prevalence further increase with advancing age
(Von Campenhausen et al., 2005; Yankner et al., 2008; Hindle,
2010). So, compared with young animals, it is more significant
that aging animals are employed into PD research. With further
insight into aging and PD, increasing importance is being attached
to develop effective therapy strategies for PD through intervening
aging-related changes and deficits using aging animals (Dauer and
Przedborski, 2003; Connolly and Lang, 2014).
Among the exposure of human to environmental chemicals, the
metals/metalloids may be the leading toxic agents detected in the
environment (Migliore and Coppedè, 2009; Chege and McColl,
2014). Iron is one of the essential trace metals for human body
and has been reported to be involved in electron transfer, oxy-
gen transport, neurotransmitter synthesis, andmyelin production
in the central nervous system (CNS) (Stankiewicz et al., 2007).
Insufficient iron intake can result in iron-deficient anemia (Anand
et al., 2014). In addition, in early human life, severe iron deficiency
can lead to impaired brain development (Lozoff and Georgieff,
2006; Radlowski and Johnson, 2013). Based on these considera-
tions, it has been recommended that while humanmilk is the pre-
ferred food source for all infants, children who are not breast-fed
or partially breast-fed should be provided with an iron-fortified
formula. Therefore, it is of interest to explore the effect of neonatal
dietary iron feeding on the CNS in aging process. Although a
previous study conducted by Kaur et al. (2007) has suggested
that increased neonatal iron intake in mice can induce an aging-
related dopaminergic neurodegeneration, which is similar to PD,
it remains unclear about the effect of increased neonatal iron treat-
ment onmotor behavior and neurotransmitters of aging male and
female animals. Silibinin, a flavonoid isolated from the herb milk
thistle (Silybum marianum L.), has been used clinically for thou-
sands of years in China and Europe as an anti-hepatotoxic agent to
treat liver diseases, especially alcoholic liver disease (Guigas et al.,
2007; Brandon-Warner et al., 2010). Silibinin has also been sug-
gested to display neuroprotective properties against various neu-
rodegenerative diseases (Lu et al., 2009; Wang et al., 2012). How-
ever, it is not clear whether silibinin is neuroprotective against
aging-related neurodegeneration in male and female animals.
In the present study, we examined the effect of increased neona-
tal dietary iron feeding on behavior and neurotransmitters inmale
and female rats with aging. Importantly, we investigated the effect
of silibinin on behavior and neurotransmitters in aging male and
female rats with increased neonatal iron intake and the underlying
mechanism.
MATERIALS AND METHODS
Animals and Treatment
All animals were purchased from Sino-British SIPPR/BKLabAni-
mal Ltd., Shanghai, China. During the course of the experiments,
all animals were treated in strict accordance with the guidelines
of the US National Institutes of Health for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, revised 1996)
and the Protocols for Animal Experimentation of Shanghai Jiao
TongUniversity School ofMedicine. All efforts weremade tomin-
imize the number of animals used and their suffering. Sprague-
Dawley rat pups were fed either saline vehicle or carbonyl iron
daily by oral gavage from days 10 to 17 post-partum. Based on the
previous studies (Schröder et al., 2001; Kaur et al., 2007), the rat
pups were fed with increased iron (120μg/g body weight). Rats
were divided into young and aging groups. The rats in young
and aging groups were aged to 200 and 600 days, respectively,
and behavior tests were performed on the rats. Then, rats were
sacrificed for further experiments. From the age of 540 days, some
aging rats was administered with silibinin (25 and 50mg/kg body
weight) every second day orally through an oral gavage needle
before scarification.
Behavior Tests
Rotarod and open field tests were carried out to evaluate animal
behavior during the light period. The basic requirements for
rotarod test were composed of a power source, a roller, and four
separators that divided the roller into equal-sized compartments.
After receiving training, rats were tested for three times at each
rotarod speed of 5, 10, and 15 rotations per minute (rpm). The
latency time to fall was recorded for each test. For locomotor
activity, each rat was placed into an open field chamber, which
is made of wood covered with impermeable formica. The cham-
ber had a white floor (100 cm 100 cm) with it divided into 25
squares (20 cm 20 cm) and 50 cm high walls. Before testing,
each animal was placed in the open field center and acclima-
tized for 10min. Rat motor behavior was recorded for 30min.
The following parameters were counted: (1) crossing number,
defined as entering of another square with all four paws and (2)
rearing number, defined as rearing with and without wall contact
(standing only on hind legs).
Neurochemical Analysis
High-performance liquid chromatography (HPLC), equipped
with electrochemical detector (ECD), was used to determine neu-
rotransmitter content in the rat striata (McNaught et al., 2004).
Briefly, rat striata were dissected on ice and weighed. Then, the
striata were homogenized (10% weight/volume) by sonication
in ice-cold homogenization buffer containing perchloric acid
(0.1mol/L). 3,4-Dihydroxybenzylamine is applied as the internal
standard. Obtained samples were centrifuged at 25,000 g and
4°C for 10min. The collected supernatants were used for the
determination of DA and serotonin (5-HT) content by HPLC-
ECD, which is equipped with a column of 5μm spherical C18
particles. The mobile phase was composed of 0.1M phosphate
buffer (pH 2.6) containing 2.5%methanol, 0.2mMoctanesulfonic
acid, and 4.5% acetonitrile. The content of each neurotransmitter
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was expressed as nanograms per gram equivalent of striatal
tissue.
Determination of Malondialdehyde (MDA)
and Glutathione (GSH)
The levels of MDA and GSH were measured according to the
manufacturer’s instruction by commercially available kits (Cay-
man Chemical Co., Ann Arbor, MI, USA). For MDA assay,
thiobarbituric acid (TBA) reacts with MDA in acidic medium at
elevated temperature to form TBA reactive product. SN tissue was
homogenized (10% weight/volume) with radioimmunoprecipi-
tation assay (RIPA) homogenizing buffer containing a protease
inhibitor. Obtained samples were centrifuged at 1,600 g and 4°C
for 10min. Then, supernatants were used for analysis. Samples
or standards (100μl) were added to 100μl of sodium dodecyl
sulfate solutions followed by the addition of 4ml of color reagents
(530mg of TBA with 50ml of diluted TBA acetic acid solution
and 50ml of diluted TBA sodium hydroxide). Obtained solu-
tions were boiled for 1 h followed by the incubation in ice bath
for 10min to stop reaction. Then, solutions were centrifuged at
1,600 g and 4°C for 10min. The absorbance values of the samples
were read at 540 nm using a microplate reader. GSH determi-
nation was based on the enzymatic recycling method. In brief,
100μl of supernatant from SN homogenate was deproteinated
by the addition of 100μl metaphosphoric acid reagent (5 g of
metaphosphoric acid in 50ml water). Then, triethanolamine
reagent (50μl/ml, 4M)was added to the solution and immediately
vortexed. Samples or standards (50μl) were pipetted into the des-
ignatedwells. This was followed by the addition of 150μl of freshly
prepared Assay Cocktail consisting of 11.25ml of MES Buffer
(0.4M 2-(N-morpholino) ethanesulphonic acid, 2mM EDTA,
and 0.1M phosphate), 0.45ml of reconstituted Cofactor Mixture
(a lyophilized powder ofNADP+ and glucose-6-phosphate recon-
stituted with 0.5ml of water), 2.1ml of reconstituted Enzyme
Mixture (glutathione reductase and glucose-6-phosphate dehy-
drogenase reconstituted in 2ml MES buffer), 2.3ml of water, and
0.45ml of reconstituted DTNB (5,50-dithio-bis-(2-nitrobenzoic
acid)). Following incubation of 25min, the absorbance value was
read at 405 nm using a microplate reader.
Statistical Analysis
Data were expressed as the mean SEM. Differences were deter-
mined by two-tailed Student’s t-test for comparison between two
groups and an analysis of variance (ANOVA) and Bonferroni
post hoc test for comparison between more than two groups. Nor-
mality of sample distribution and homogeneity of variances were
tested before each ANOVA. A value of p <0.05 was considered
statistically significant.
RESULTS
Increased Neonatal Iron Intake Resulted in
Significant Behavior Abnormality and
Striatal DA Depletion in Male and
Female Rats with Aging
Rotarod and open field tests were carried out to evaluate the effect
of neonatal iron intake onmotor behavior of young and aging rats
(male and female). As shown in Figures 1 and 2, neonatal iron
(120μg/g body weight) intake did not lead to significant change
in behavior of the young male and female rats in comparison
with the vehicle-treated rats. However, significant decreases in
latency time [aging male rats: p< 0.005 (5 and 10 rpm), p< 0.01
(15 rpm); aging female rats: p< 0.01 (5, 10, and 15 rpm)] and
the number of crossing and rearing [aging male rats: p< 0.01
(crossing number), p< 0.005 (rearing number); aging female rats:
p< 0.01 (crossing number and rearing number)] were observed
in the aging male and female rats with neonatal intake of the
same dose of iron in comparison with the vehicle-treated rats
(Figures 1 and 2). In agreement with behavior tests, the neona-
tal iron intake did not lead to significant depletion of striatal
DA in the young male and female rats in comparison with the
vehicle-treated rats (Figures 3A,B). However, significant decrease
in striatal DA content (p< 0.005) was observed in the aging
male and female rats with neonatal iron intake compared with
the vehicle-treated rats (Figures 3A,B). Although the neona-
tal iron intake significantly reduced the content of striatal DA
in the aging male and female rats compared with the vehicle-
treated rats, no significant change in the content of striatal 5-
HT was observed in the aging male and female rats with the
neonatal iron intake in comparison with the vehicle-treated rats
(Figures 3C,D).
Increased Neonatal Iron Intake Resulted in
Significant MDA Increase and GSH
Decrease in Male and Female Rats
with Aging
We further investigated the effect of neonatal iron intake on
the content of MDA and GSH in the SN of the young and
aging rats (male and female). As shown in Figure 4, the neona-
tal iron intake did not result in significant change in the con-
tent of MDA and GSH in the SN of the young male and
female rats compared with the vehicle-treated rats. However,
significant increase in MDA content (p< 0.005) and decrease in
GSH content (p< 0.005) were observed in the SN of the aging
male and female rats with neonatal intake of the same dose of
iron in comparison with the vehicle-treated rats. Although the
neonatal iron intake significantly increased MDA content and
decreased GSH content in the SN of the aging male and female
rats compared to the rats treated with vehicle, no significant
change in the content of MDA and GSH was observed in the
cerebellum (CBM) of the aging male and female rats with the
neonatal iron intake in comparison with the vehicle-treated rats
(Figure 5).
Silibinin Significantly and
Dose-Dependently Diminished Striatal DA
Depletion and Improved Behavioral
Abnormality in Aging Male and Female
Rats with Increased Neonatal Iron Intake
We further investigated the effect of silibinin (25 and 50mg/kg
body weight) treatment on striatal DA depletion and behavioral
abnormality in the aging rats (male and female) with increased
neonatal iron intake. As shown in Figure 6, although silibinin
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FIGURE 1 | Increased neonatal iron intake resulted in significant behavior abnormality (rotarod test) in male (A,B) and female (C,D) rats with aging
[(A,C): young; (B,D): aging]. Results are expressed as meanSEM. N= 8–10. #p<0.01, +p<0.005, compared with the aging rats treated with Veh. Veh, vehicle.
FIGURE 2 | Increased neonatal iron intake resulted in significant behavior abnormality (open-field test) in male (A,B) and female (C,D) rats with aging
[(A,C): young; (B,D): aging]. Results are expressed as meanSEM. N= 8–10. #p<0.01, +p<0.005, compared with the aging rats treated with Veh. Veh, vehicle.
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FIGURE 3 | Increased neonatal iron intake resulted in significant striatal DA depletion in male (A,C) and female (B,D) rats with aging. Results are
expressed as meanSEM. N= 8–10. +p<0.005, compared with the aging rats treated with Veh. DA, dopamine; 5-HT, serotonin; Veh, vehicle.
FIGURE 4 | Increased neonatal iron intake resulted in significant MDA (A,C) increase and GSH (B,D) decrease in the SN of male (A,B) and female (C,D)
rats with aging. Results are expressed as meanSEM. N= 8–10. +p<0.005, compared with the aging rats treated with Veh. MDA, malondialdehyde; GSH,
glutathione; SN, substantia nigra; Veh, vehicle.
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FIGURE 5 | Effect of increased neonatal iron intake on MDA (A,B) increase and GSH (C,D) content in the CBM of aging male (A,C) and female (B,D)
rats with aging. Results are expressed as meanSEM. N= 8–10. +p<0.005, compared with the aging rats treated with Veh. MDA, malondialdehyde; GSH,
glutathione; SN, substantia nigra; CBM, cerebellum; Veh, vehicle.
FIGURE 6 | Effect of silibinin treatment on motor behavior of aging male (A,C) and female (B,D) rats with increased neonatal iron intake in rotarod test
(A,B) and open-field test (C,D). Results are expressed as meanSEM. N= 8–10. *p<0.05, #p<0.01, and +p<0.005, compared with the aging rats treated
with Veh. Veh, vehicle.
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FIGURE 7 | Effect of silibinin treatment on striatal DA content and SN MDA and GSH content in aging male (A,C) and female (B,D) rats with increased
neonatal iron intake. Results are expressed as meanSEM. N= 8–10. *p<0.05, #p<0.01, and +p<0.005, compared with the aging rats treated with Veh. DA,
dopamine; Veh, vehicle; MDA, malondialdehyde; GSH, glutathione.
treatment at the dose of 25mg/kg bodyweight did not significantly
change motor behavior in the aging male and female rats with
the neonatal iron intake compared with the vehicle-treated rats,
motor behavior of the aging male and female rats with increased
neonatal iron intake was significantly improved [aging male rats:
p< 0.005 (5 and 15 rpm), p< 0.01 (10 rpm), p< 0.01 (crossing
and rearing number); aging female rats: p< 0.01 (5 and 15 rpm),
p< 0.05 (10 rpm), p< 0.01 (crossing and rearing number)] after
silibinin administration at the dose of 50mg/kg body weight.
In agreement with behavior tests, neurochemical analysis also
demonstrated that silibinin administration at the doses of 25 and
50mg/kg body weight significantly diminished depletion of stri-
atal DA in the aging male and female rats with increased neonatal
iron intake compared with the vehicle-treated rats [aging male
rats: p< 0.01 (25mg/kg), p< 0.005 (50mg/kg); aging female rats:
p< 0.05 (25mg/kg), p< 0.005 (50mg/kg)] (Figures 7A,B).
Silibinin Significantly Reduced MDA
Content and Increased GSH Content in the
SN of the Aging Male and Female Rats with
Increased Neonatal Iron Intake
We finally examined the effect of silibinin treatment onMDA and
GSH levels in aging rats with increased neonatal iron intake. As
shown in Figures 7C,D, at the doses of 25 and 50mg/kg body
weight, silibinin administration significantly reduced the content
of MDA and increased the content of GSH in the SN of the
agingmale and female rats with the increased neonatal iron intake
compared with the vehicle-treated rats [p< 0.05 (25mg/kg) and
p< 0.005 (50mg/kg)].
DISCUSSION
Many evidences have demonstrated that aging is a critical risk
factor for idiopathic PD in recent years (Yankner et al., 2008;
Gureviciene et al., 2009; Hindle, 2010). PD is rarely occurred
before the age of 50 years for humans. Its incidence and prevalence
increase with aging. Also, aging people gradually exhibit some
characteristics of PD, including Lewy bodies, striatal DA decrease,
and motor signs, which are similar to those seen in PD. In the
mice with increased neonatal dietary iron feeding, Kaur et al.
(2007) found increased SN iron level at the age of 3months,
increased oxidative stress markers and reduced striatal DA level
at 12, 16, and 24months, but not at 2months, when compared
with the control mice. They also found significant reduction in
the number of tyrosine hydroxylase-immunoreactive neurons in
the iron-fed animals in comparison with the control animals at
the age of 24months, but not at 2, 12, and 16months. In the
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present study, our results indicated that increased neonatal iron
(120μg/g body weight) feeding induced significant abnormal-
ity of behavior and depletion of striatal DA in the aging male
and female rats while it did not do so in the young male and
female rats. Moreover, no significant change in the content of
striatal 5-HT was observed in the aging male and female rats
with neonatal intake of the same dose of iron. These results
mentioned above suggested that elevated neonatal iron intake
alone, given enough time, might lead to some features of PD. In
addition, there was no significant change in striatal 5-HT content
in the aging male and female rats, indicating the selectivity of
neurotoxicity. Our results show that elevated neonatal iron sup-
plementation has long-lasting effects, and it possibly represent a
novel risk factor for aging-related dopaminergic neurodegenera-
tion. The possible neurotoxicity of increased neonatal iron sup-
plementation observed in the present work should be taken into
consideration and certainly warrants further studies in humans
especially because it affects the CNS in aging process. It is of
interest for the development of effective treatments to diminish
aging-related dopaminergic neurotoxicity as a consequence of
elevated neonatal iron supplementation in aging male and female
animals.
Silibinin is the major active component of silymarin extracted
from milk thistle. By employing a ThT assay and electron micro-
scopic imaging, Yin et al. (2011) identified that silibinin appears
to act as a novel inhibitor of amyloid β (Aβ) aggregation and
this effect showed dose-dependency. They also observed that
silibinin protected SH-SY5Y cells from injuries caused by Aβ1-
42-induced oxidative stress by decreasing H2O2 production in
Aβ1-42-stressed neurons. Tota et al. (2011) showed that treat-
ment with silibinin prevented streptozotocin-induced memory
loss in mice. They further demonstrate that beneficial effect
of silibinin in animals is contributed to improvement in brain
energy metabolism and cholinergic function. Silibinin was also
demonstrated to attenuate cognitive deficits and decreases of DA
and 5-HT induced by repeated methamphetamine treatment (Lu
et al., 2010). Jung et al. (2014) observed that silibinin admin-
istration attenuated MPP+-induced neurotoxicity in the SN in
a dose-dependent manner. They also observed that increased
levels of inflammatory molecules, such as tumor necrosis factor-
alpha, interleukin-1 beta, and inducible nitric oxide synthase
by MPP+ treatment, were attenuated by treatment with silib-
inin. Moreover, Geed et al. (2014) showed that silibinin pretreat-
ment diminished biochemical and behavioral changes induced
by intrastriatal MPP+ injection in rats. In the present study,
we found that silibinin treatment significantly improved motor
abnormality and diminished striatal DA depletion of the aging
male and female rats with increased neonatal iron intake, indi-
cating the potential dopaminergic neuroprotection of silibinin
in PD.
Oxidative stress is demonstrated to be involved in aging pro-
cess and cell injury (Bodhinathan et al., 2010; Argüelles et al.,
2011; Cui et al., 2012; Sykora et al., 2013; Kamarudin et al.,
2014). Redox imbalance may play an important role in various
neurodegenerative diseases (Campos et al., 2014; Lee et al., 2014;
Navarro-Yepes et al., 2014; Rivas-Arancibia et al., 2015; Wang
et al., 2015). Content of MDA, lipids, and cholesterol hydroper-
oxides was observed to be increased in PD (Dexter et al.,
1989, 1994). MDA, as the most cytotoxic aldehyde derived
from the process of lipid peroxidation, reflects oxidative dam-
age to lipids, and it has been observed to be significantly ele-
vated in the SN of PD patients in comparison with other brain
regions and control tissues (Esterbauer et al., 1991; Ross et al.,
1998; Navarro-Yepes et al., 2014). GSH is an antioxidant existed
in animal cells. It is an essential ubiquitous thiol tripeptide.
Through reacting with free radicals and decreasing superoxide
radicals, hydroxyl radicals, and peroxynitrites, GSH was shown
to play an important role in cell protection. GSH has also been
demonstrated to be involved in various biological processes,
including DNA synthesis and repair, protein synthesis, enzy-
matic reaction, and cellular immunity (Cui et al., 2012; Navarro-
Yepes et al., 2014). GSH decrease is exhibited in the SN of
some PD animal models and PD patients (Ferraro et al., 1986;
Navarro-Yepes et al., 2014). In the present study, we observed
that increased neonatal iron intake resulted in significant MDA
increase and GSH reduction in the SN of the male and female
rats with aging. However, no significant change in the con-
tent of cerebellar MDA and GSH was observed in the aging
male and female rats with increased neonatal iron intake. We
also observed that silibinin significantly decreased the content
of MDA and increased the content of GSH in the aging male
and female rats with increased neonatal iron intake. Our results
indicate that redox imbalance may be involved in dopamin-
ergic neurodegeneration of aging male and female rats with
increased neonatal iron intake and recovering balance of redox
in the tissue microenvironment may be one of the most likely
mechanisms by which silibinin exerts neuroprotective effects
in aging male and female rats with increased neonatal iron
intake.
In conclusion, our study suggests that elevated neonatal iron
supplementation may induce PD-like neurochemical and behav-
ioral deficits with aging and silibinin may be neuroprotective
in PD. Maintaining redox balance may be one of the mech-
anisms underlying silibinin’s neuroprotection. Further study
is required to fully understand the potential role of neona-
tal iron intake and silibinin in aging process and PD and to
develop effective therapeutic strategies to slow aging and PD
neurodegeneration.
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